Acrivon Therapeutics, Inc. (ACRV)

NASDAQ: ACRV · IEX Real-Time Price · USD

8.86

+0.49 (5.85%)

At close: Jul 26, 2024, 4:00 PM

8.93

+0.07 (0.79%)

After-hours: Jul 26, 2024, 6:36 PM EDT

Acrivon Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	22.64	21.08	8.71	2.47	1.3
Research & Development	47.74	46.02	23.95	13.72	1.87
Operating Expenses	70.38	67.1	32.66	16.18	3.17
Operating Income	-70.38	-67.1	-32.66	-16.18	-3.17
Interest Expense	-0.36	-	-	-	-
Interest & Investment Income	-	-	-	-	0.03
Other Non Operating Income (Expenses)	3.3	3.39	0.79	-0.06	-0.07
EBT Excluding Unusual Items	-67.44	-63.71	-31.87	-16.24	-3.21
Gain (Loss) on Sale of Investments	3.32	3.32	0.7	-	-
Other Unusual Items	-	-	-	-	-2.1
Pretax Income	-64.12	-60.39	-31.17	-16.24	-5.31
Net Income	-64.12	-60.39	-31.17	-16.24	-5.31
Net Income to Common	-64.12	-60.39	-31.17	-16.24	-5.31
Shares Outstanding (Basic)	22	22	4	2	1
Shares Outstanding (Diluted)	22	22	4	2	1
Shares Change (YoY)	142.87%	435.63%	136.43%	21.70%	-
EPS (Basic)	-2.88	-2.74	-7.56	-9.32	-3.70
EPS (Diluted)	-2.88	-2.74	-7.56	-9.32	-3.70
Free Cash Flow	-50.45	-43.93	-32.28	-14.22	-2.82
Free Cash Flow Per Share	-2.27	-1.99	-7.83	-8.16	-1.97
EBITDA	-69.74	-66.57	-32.29	-16.15	-3.16
D&A For EBITDA	0.64	0.54	0.36	0.04	0.01
EBIT	-70.38	-67.1	-32.66	-16.18	-3.17

Source: S&P Capital IQ. Standard template.